ARTHROBOT Joint Replacement Surgical Robot

ARTHROBOT, developed by Hangzhou Jianjia Medical Technology, became China’s first domestically manufactured joint replacement surgical robot to achieve commercial sales. The system earned multiple NMPA approvals between 2022 and 2023, establishing a unified platform capable of supporting both hip and knee arthroplasty procedures with robotic precision.

Product Overview

The ARTHROBOT platform addresses a fundamental challenge in joint replacement surgery: achieving consistent, accurate implant positioning regardless of surgeon experience level. Traditional manual techniques depend heavily on individual skill and spatial judgment, leading to variable outcomes and extended learning curves. By incorporating robotic assistance with optical navigation, ARTHROBOT aims to standardize surgical precision while reducing procedure-related radiation exposure for operating room staff.

Jianjia designed ARTHROBOT specifically for the Chinese healthcare environment, where rising demand for joint replacements coincides with policy emphasis on domestically manufactured medical equipment. The system competes primarily against Stryker’s Mako platform, which previously dominated China’s robotic joint surgery market.

Key Features

Seven-Axis Robotic Arm: Unlike conventional six-axis configurations, ARTHROBOT’s additional degree of freedom enhances maneuverability in anatomically constrained surgical fields, particularly relevant for hip procedures where access angles significantly impact implant placement.

Optical Positioning System: Real-time infrared tracking monitors the spatial relationship between surgical instruments, anatomical landmarks, and implant components throughout the procedure, enabling dynamic navigation updates.

Safety Boundary Control: The system prevents the robotic arm from exceeding surgeon-defined safe zones, protecting critical structures including nerves and blood vessels from inadvertent contact.

Integrated Surgical Planning: Preoperative software processes CT imaging data to generate patient-specific surgical plans, including optimal implant sizing, positioning angles, and bone resection parameters.

Technical Specifications

At ≤1 mm linear and ≤1° angular positioning accuracy, Jianjia’s ARTHROBOT uses a 7-axis robotic arm with optical infrared tracking to guide hip and knee arthroplasty procedures, NMPA approved from April 2022.

Clinical Applications

ARTHROBOT received its first NMPA Class III medical device registration in April 2022 for total hip arthroplasty, earning innovative medical device designation. Subsequent approvals expanded the platform’s indicated uses:

Total Hip Arthroplasty (THA): The system assists with acetabular preparation (reaming and cup positioning), femoral osteotomy, and prosthesis installation. Applicable conditions include primary osteoarthritis, avascular necrosis (Ficat/ARCO Stage III-IV), inflammatory arthritis, and displaced femoral neck fractures.

Total Knee Arthroplasty (TKA): Approved in January 2023, knee applications use the same platform with procedure-specific instruments and planning modules for tibial and femoral component placement.

Multi-Application Configuration: The August 2023 approval consolidated hip and knee capabilities into a single unified system, eliminating the need for separate installations.

Published clinical research, including a multicenter randomized controlled trial, demonstrates improved acetabular cup positioning accuracy with the ARTHROBOT system compared to conventional manual techniques. The study, conducted across three tertiary hospitals in China, showed statistically significant reductions in component malpositioning rates.

Regulatory Status

ARTHROBOT’s hip replacement system was designated as an innovative medical device by NMPA in February 2021, qualifying for expedited review. This designation recognizes products with novel technical principles and significant clinical advantages over existing solutions.

Commercial Deployment

As of mid-2023, ARTHROBOT systems had been installed in multiple Chinese hospitals through public procurement processes. Contract values have ranged from approximately ¥7.9 million to ¥11.2 million depending on configuration, instrument packages, and service terms. The system’s pricing positions it below imported alternatives, aligning with healthcare cost containment initiatives and domestic equipment procurement preferences.

Clinical utilization data indicates cumulative procedure counts exceeding expectations for newly introduced surgical robot platforms, suggesting reasonable adoption rates among trained orthopedic surgeons.

Frequently Asked Questions

How does ARTHROBOT compare to Stryker Mako?

Both systems provide robotic assistance for joint replacement with preoperative planning and intraoperative navigation. ARTHROBOT uses a seven-axis robotic arm, while Mako employs a different kinematic design. Clinical outcomes data remains limited for direct comparison, though both platforms demonstrate improved component positioning versus manual techniques. Price differentiation favors ARTHROBOT in the Chinese market.

What training is required to use ARTHROBOT?

Surgeons undergo manufacturer-provided training covering system operation, surgical planning software, and procedure-specific protocols. The learning curve is generally considered shorter than for manual techniques, as the robotic assistance compensates for some aspects of surgical experience.

Can ARTHROBOT be used for revision surgery?

The current NMPA approvals primarily cover primary joint replacement procedures. Complex revision cases with significant bone loss or deformity may fall outside standard indicated uses and require clinical judgment regarding robotic applicability.